Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

CHICAGO, May 7 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced its financial results for the first quarter ended March 31, 2008. The net loss available to common shareholders for the three months ended March 31, 2008 was $3.6 million or ($0.09) per share compared to $10.5 million or ($0.37) per share for the three months ended March 31, 2007. The decrease in the net loss reflects lower development expenses related to the cethromycin pivotal Phase III clinical program, which was completed in November 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

"Having confirmed the regulatory plans for cethromycin, we are pushing forward aggressively to achieve our partnering and NDA submission goals," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "We believe cethromycin can be an important new drug in the treatment of community acquired pneumonia and, if approved, can assist in the emerging battle against drug resistant bacteria."

The company ended the first quarter of 2008 with cash and cash equivalents totaling $12.6 million. Cash used during the first quarter was approximately $5.7 million.

Operating Expense Analysis:

* Research and development expense. Total research and development

expense decreased $7.2 million to approximately $1.9 million for the

three months ended March 31, 2008 from approximately $9.1 million for

'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...19 Bavarian Nordic,has ...e payment of USD 25,million as allowed under the ...ion doses of the company,s IMVAMUNE(R) smallpox va...e recent submission of a clinical safety report,f... infected subjects, which,is part of the regulato...
(Date:11/19/2008)...ire/ -- Arete Therapeutics Inc., a,privately-held...oluble epoxide,hydrolase (s-EH) inhibitors, today...f its Series A financing. Frazier Healthcare Ventu...anche, which also included existing,investors Bur...ude Life Science,Ventures. This financing comple...
(Date:11/19/2008)...- Kornberg Associates Architects,( http://www.kor... has also been,retained by the Okinawa Institute ...a new government funded scientific research campus... and founder, made the announcement. , "Hav... and further,solidifies our international capabil...
(Date:11/18/2008)...-- PETLinQ(R) LLC is extremely proud to,announce ...llections system,for the Mac platform. RISLinQ(R)...ity for radiology facilities presently using the M... CEO of PETLinQ, states, "The Mac OS X platform,i...e operating system that,many radiologists and the...
Breaking Biology Technology:Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities 2Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 2Kornberg Associates Architects Opens Tokyo Office 2PETLinQ Launches RISLinQ 4.0Mac on Mac OS X Platform 2
...sconsin companies recently won CIO magazines CIO...their resourcefulness regarding the use of informa...ant Energy, Lands End, Manpower Inc., Maysteel and...e August 15 issue of the magazine. Alliant Energy .... , ,The magazine says the 100 honorees were chose...
...uters are the source of problem , ,Madison, WI- O...-Madison campus were infected with the latest e-ma...led that beginning in May 2003, UW-Madison discove...e scale flood of inbound Internet traffic destined...ol (NTP) servers. NTP servers are used to synchron...
...ncement that TechStar will receive a two-year gran...est sign that research institutions in Milwaukee, ...son in pushing technology into the marketplace, ar...kee - which means good news for the Wisconsin econ...m an old-line manufacturing burg to a center of ad...
... field and navigating at the helm of several compa...es (which is located in Woodridge, Ill. across fr...opportunity to fund and advance his drug discovery...riod, Flavin says hell be hitting the road in the ... to raise about $30 million in funding. , ,Flavin...
Other Biology Technology:Five Wisconsin Non-Tech Companies Win IT Awards 2Five Wisconsin Non-Tech Companies Win IT Awards 3Five Wisconsin Non-Tech Companies Win IT Awards 4Flawed Routers Flood UW Server 2Flawed Routers Flood UW Server 3Milwaukee research institutions step up the pace for technology transfer 2Advanced Life Sciences to Hit the Road For $30 Million in Funding 2Advanced Life Sciences to Hit the Road For $30 Million in Funding 3Advanced Life Sciences to Hit the Road For $30 Million in Funding 4
(Date:11/19/2008)... University scientists on the hunt for a better wa...ted a method that lets them watch molecules break ...emical bonds are formed and broken. , "We can se... our molecules," said researcher Michael Wong. "By...y and intensity with time, we can watch how molecu...
(Date:11/19/2008)...icultural research will convene more than 700 lead...rs and donor representatives in Maputo, Mozambique...hes for meeting the food needs of the poor in Afri...tem to its coreclimate change, skyrocketing food p...e financial crisis. In just the past three years, ...
(Date:11/19/2008)...a (windpipe), utilising the patient,s own stem cel...g woman with a failing airway. The bioengineered t...mally functioning airway, thereby saving her life.... evidence that adult stem cells, combined with bio...solutions to other serious illnesses. , In parti...
(Date:11/19/2008)...s to predict that a person will develop type 2 dia...in is produced in the pancreas and is the hormone ...ral tissues and organs in the body, such as muscle... of tissue response to insulin and is counteracted...s. When the pancreas does not have the capacity to...
Breaking Biology News(10 mins):Researchers shed new light on catalyzed reactions 2Researchers shed new light on catalyzed reactions 3Major conference on food Dec. 1-2, 2008 2Adult stem cell breakthrough 2Adult stem cell breakthrough 3Researchers at IRB Barcelona produce more data on key genes in diabetes 2Researchers at IRB Barcelona produce more data on key genes in diabetes 3EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference 19149 1EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference 19149 2Visage Imaging to Provide Fully Integrated Thin Client Based Solution to Tufts Medical Center 19144 1Visage Imaging to Provide Fully Integrated Thin Client Based Solution to Tufts Medical Center 19144 2Visage Imaging to Provide Fully Integrated Thin Client Based Solution to Tufts Medical Center 19144 3Cipher provides regulatory update for CIP TRAMADOL ER 19143 1Cipher provides regulatory update for CIP TRAMADOL ER 19143 2Cipher provides regulatory update for CIP TRAMADOL ER 19143 3Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness Increases Patient Safety 19141 1Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness Increases Patient Safety 19141 2Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness Increases Patient Safety 19141 3
...tentially ground-breaking treatment for nerve dama...in preclinical and early patient trials. , The Uni...ection of a novel therapeutic that works by stimul...rimarily to the hands and feet ?caused by the dise... in the journal Diabetes ?are further evidence tha...
...otein that allows breast cancer cells to evade the... of future cancer therapies, according to a study ...the University of Southern California. , The st... Journal of Pathology, is the first to identify ho...ls ?functions. , "The important aspect of this s...
...archers have discovered the genetic controls which... fall, as well as the mechanism that causes them t...forward in understanding the basic genetics of tre...rom the Swedish University of Agricultural Science...ons, and published in the journal Science. They re...
...ortable living is not why so many different life f...lanet. , Writing this week in the Proceedings of t...gher temperatures near the equator speed up the me...ges that actually lead to the creation of new spec...ersity of Florida, the National Center for Ecologi...
Other Biology News:Trial success for diabetic nerve therapy 2USC researchers investigate protein that protects tumors 2Discovery may speed forest biotechnology 2Discovery may speed forest biotechnology 3Taking evolution's temperature: Researchers pinpoint the energy it takes to make a species 2Taking evolution's temperature: Researchers pinpoint the energy it takes to make a species 3
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C
Request Info
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12
Polyclonal Antibody to CLAN
Biology Products: